Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MRVT Miravant Med Tech: Infinity and Beyond? -- Ignore unavailable to you. Want to Upgrade?

To: Alan Gallaspy who wrote (62)	1/15/2002 5:17:08 PM
From: Ian@SI	Read Replies (1) \| Respond to of 67

As SnET2 was the most advanced potential competitor from a Clinical Trial perspective, its failure should have a positive impact on QLT's future revenue stream. Either the market had already discounted this in QLTI's price but not in MRVT's; or it doesn't seem to much care. QLTI is actually trading at a lower price now than prior to MRVT's announcement of the SnET2 failure. Visudyne remains the only AMD treatment with proven effectiveness and will hold that monopoly for several years at least.